Optimizing a Lupus Autoantibody for Targeted Cancer Therapy

These findings offer a preclinical proof of principle for the use of an optimized nuclear-penetrating autoantibody against DNA as a targeted therapy for tumors with preexisting defects in homology-directed repair.